New Horizon Health (DB:6YZ) - Stock Price, News & Analysis

6YZ Stock Overview

An investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. More details

6YZ fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 88.9% below our estimate of its fair value

Earnings are forecast to grow 60.45% per year

Became profitable this year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

New Horizon Health Limited Competitors

SYNLAB

HMSE:SYAB

€2.5b

Fresenius Medical Care

XTRA:FME

€12.2b

RHÖN-KLINIKUM

XTRA:RHK

€850.1m

Medios

XTRA:ILM1

€335.7m

Price History & Performance

Summary of all time highs, changes and price drops for New Horizon Health
Historical stock prices
Current Share Price	HK$1.62
52 Week High	HK$3.28
52 Week Low	HK$1.60
Beta	1.27
11 Month Change	0%
3 Month Change	-11.96%
1 Year Change	-48.73%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-49.45%

Recent updates

Shareholder Returns

	6YZ	DE Healthcare	DE Market
7D	0%	0.3%	-1.3%
1Y	-48.7%	15.7%	7.4%

Return vs Industry: 6YZ underperformed the German Healthcare industry which returned -1.5% over the past year.

Return vs Market: 6YZ underperformed the German Market which returned 3.1% over the past year.

Price Volatility

Is 6YZ's price volatile compared to industry and market?
6YZ volatility
6YZ Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6YZ's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 6YZ's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	1,041	Yeqing Zhu	ir.newhorizonbio.com

New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities.

New Horizon Health Limited Fundamentals Summary

How do New Horizon Health's earnings and revenue compare to its market cap?
6YZ fundamental statistics
Market cap	€757.51m
Earnings (TTM)	€14.34m
Revenue (TTM)	€174.90m

52.8x

P/E Ratio

4.3x

P/S Ratio

Is 6YZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6YZ income statement (TTM)
Revenue	CN¥1.36b
Cost of Revenue	CN¥153.40m
Gross Profit	CN¥1.21b
Other Expenses	CN¥1.10b
Earnings	CN¥111.70m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.25
Gross Margin	88.74%
Net Profit Margin	8.20%
Debt/Equity Ratio	12.7%

How did 6YZ perform over the long term?

See historical performance and comparison

New Horizon Health DB:6YZ Stock Report